Lebertransplantation bei Erwachsenen – aktuelle Herausforderungen

Der Spenderorganmangel und die Möglichkeiten, diesen abzumildern – seit Jahren die größte Herausforderung in der Lebertransplantation. Darüber hinaus verändert sich das Kollektiv der potenziellen Organempfänger und der Transplantierten, was neue medizinische/ethische Fragen aufwirft. Dieser Beitrag gibt einen Überblick über den aktuellen Stand der Indikationsstellung, der Spender- und Organbehandlung und der Therapie vor und nach Transplantation.

Schlüsselwörter

Lebertransplantation - hepatozelluläres Karzinom - Lebendspende - Spenderorganmangel

• Literatur

• 1 Bundesgesundheitsministerium. Transplantationsgesetz (TPG). Im Internet: http://www.bundesgesundheitsministerium.de/themen/praevention/organspende/regelung-der-organspende.html Stand: 24.8.2017
• 2 Starzl TE, Marchioro TL, Porter KA. et al. Factors determining short- and long-term survival after orthotopic liver homotransplantations in the dog. Surgery 1965; 58: 131-155
• 3 Taniguchi M. Liver transplantation in the MELD era – analysis of the OPTN/UNOS registry. Clin Transpl 2012; 27: 41-65
• 4 Weismüller TJ, Fikatas P, Schmidt J. et al. Multicentric evaluation of model for end-stage liver disease-based allocation and survival after liver transplantation in Germany – limitations of the “sickest first”-concept. Transpl Int 2011; 24: 91-99
• 5 Mazzaferro V, Regalia E, Doci R. et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-699
• 6 Deutsche Stiftung Organtransplantation. Lebertransplantation. Im Internet: https://www.dso.de/organspende-und-transplantation/transplantation/lebertransplantation.html Stand: 24.08.2017
• 7 Samstein B, Smith AR, Freise CE. et al. Complications and their resolution in recipients of deceased and living donor liver transplants: findings from the A2ALL cohort study. Am J Transplant 2016; 16: 594-602
• 8 Adam R, Karam V, Delvart V. et al. Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). J Hepatol 2012; 57: 675-688
• 9 Settmacher U, Götz M, Rahmel A. et al. Living donor liver transplantation in adults in the MELD era in Germany – a multi-center retrospective analysis. Transpl Int 2011; 24: 904-911
• 10 Dew MA, Butt Z, Humar A. et al. Long-term medical and psychosocial outcomes in living liver donors. Am J Transplant 2017; 17: 880-892
• 11 Ceresa CDL, Nasralla D, Knight S. et al. Cold storage or normothermic perfusion for liver transplantation: probable application and indications. Curr Opin Organ Transplant 2017; 22: 300-305
• 12 Ravikumar R, Leuvenink H, Friend PJ. Normothermic liver preservation: a new paradigm?. Transpl Int 2015; 28: 690-699
• 13 Dutkowski P, Polak WG, Muiesan P. et al. First comparison of hypothermic oxygenated perfusion versus static cold storage of human donation after cardiac death liver transplants: an international-matched case analysis. Ann Surg 2015; 262: 764-770 discussion 770–771
• 14 Bruinsma BG, Avruch JH, Weeder PD. et al. Functional human liver preservation and recovery by means of subnormothermic machine perfusion. J Vis Exp 2015;
• 15 Chapman WC, Vachharajani N, Collins KM. et al. Donor age-based analysis of liver transplantation outcomes: short- and long-term outcomes are similar regardless of donor age. J Am Coll Surg 2015; 221: 59-69
• 16 Bertuzzo VR, Cescon M, Odaldi F. et al. Actual risk of using very aged donors for unselected liver transplant candidates: a european single-center experience in the MELD era. Ann Surg 2017; 265: 388-396
• 17 Persad G, Wertheimer A, Emanuel EJ. Principles for allocation of scarce medical interventions. Lancet 2009; 373: 423-431
• 18 Merion RM, Schaubel DE, Dykstra DM. et al. The survival benefit of liver transplantation. Am J Transplant 2005; 5: 307-313
• 19 Schnitzbauer AA, Welker M, Wilke HJ. et al. A proposal for an algorithm enhancing transparency and achieving harmonization for patient selection in rescue allocation for liver allografts in Germany. Langenbecks Arch Surg 2013; 398: 917-918
• 20 Mazzaferro V, Llovet JM, Miceli R. et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009; 10: 35-43
• 21 Yao FY, Ferrell L, Bass NM. et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001; 33: 1394-1403
• 22 Duvoux C, Roudot-Thoraval F, Decaens T. et al. Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria. Gastroenterology 2012; 143: 986-994 quiz e14–e15
• 23 Otto G, Herber S, Heise M. et al. Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma. Liver Transplant 2006; 12: 1260-1267
• 24 Ioannou GN. Transplant-related survival benefit should influence prioritization for liver transplantation especially in patients with hepatocellular carcinoma. Liver Transplant 2017; 23: 652-662
• 25 Belli LS, Duvoux C, Berg T. et al. ELITA consensus statements on use of DAAs in liver transplant candidates and recipients. J Hepatol 2017; 67: 585-602
• 26 Herzer K, Strassburg CP, Braun F. et al. Selection and use of immunosuppressive therapies after liver transplantation: current German practice. Clin Transplant 2016; 30: 487-501
• 27 Geissler EK, Schnitzbauer AA, Zülke C. et al. Sirolimus use in liver transplant recipients with hepatocellular carcinoma: a randomized, multicenter, open-label phase 3 trial. Transplantation 2016; 100: 116-125
• 28 Neuberger JM, Bechstein WO, Kuypers DR. et al. Practical recommendations for long-term management of modifiable risks in kidney and liver transplant recipients: a guidance report and clinical checklist by the Consensus on Managing Modifiable Risk in Transplantation (COMMIT) Group. Transplantation 2017; 101 (4S Suppl. 2): S1-56